Bio-Rad Laboratories (BIO): are the analysts right?

Bio-Rad Laboratories · Health Care · ref. ETF XLV · 50 calls · price $296.42
What the company does: Bio-Rad Laboratories fabrique et distribue des produits de diagnostic clinique.
📈 1-year price
$292.5+16.7% over range
Jul 8, 25low $241.71 · high $339.75Jul 7, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 2 analysts
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.

🎯 Analyst price target on BIO

High target · 1 analyst$300+1.2%
Median target · 2 analysts$295-0.5%
Low target · 1 analyst$290-2.2%
Current price$296.42

🗳️ The analyst consensus

Analyst breakdown · 2 (6 months)
Strong Buy0%
Buy0%
Hold100%
Sell0%
Strong Sell0%

✅ Historical analyst reliability on BIO

Most reliable analysts on BIO (% profitable · 365j · ≥2 calls)
Citigroup 50% +12.5% 10
UBS 50% -3.9% 4
Wells Fargo 40% +5.0% 5
RBC Capital 9% -15.2% 11
Credit Suisse 0% -24.4% 5

📊 What $1,000 invested in Bio-Rad Laboratories would be worth

In short — $1,000 invested in Bio-Rad Laboratories 10 years ago would be worth $2,301 today, i.e. +9%/yr on average. Best year: 2020 (+59%), worst: 2023 (-31%). Price performance, excluding dividends.

If I'd invested $1,000 in Bio-Rad Laboratories

InvestmentWorth todayGain
1 years ago$814-19%
3 years ago$628-37%
5 years ago$512-49%
10 years ago$2,301+130%
since inception (1984)$116,581+11558%

Return by year (Bio-Rad Laboratories)

YearReturn$1,000 invested at year start
2026 (YTD)0%$1,000 (0%)
2025-19%$814 (-19%)
2024+12%$915 (-9%)
2023-31%$628 (-37%)
2022-22%$490 (-51%)
2021+5%$512 (-49%)
2020+59%$814 (-19%)
2019+44%$1,175 (+18%)
2018-3%$1,136 (+14%)
2017+36%$1,545 (+54%)
2016+49%$2,301 (+130%)
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

🔎 Detailed analyses

👥 Analysts & forecasts📊 Returns & performance
📈 Fundamentals, technical momentum and live news will show here on the final site (loaded live from the same origin as the API).

📋 All analyst calls on BIO

Wells Fargo
May 1, 26
■ Equal-Weight neutral · not a buy · 🎯$290
Price at call : $257.86 — gap to target +12%
Today : $296.42 — gap to target -2%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : May 1, 27
Citigroup
Apr 7, 26
■ Neutral neutral · not a buy · 🎯$300
Price at call : $278 — gap to target +8%
Today : $296.42 — gap to target +1%
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
in progress (365j)
matures : Apr 7, 27
Wells Fargo
Feb 16, 26
■ Equal-Weight neutral · not a buy · 🎯$320
Price at call : $264.93 — gap to target +21%
Today : $296.42 — gap to target +8%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Feb 16, 27
Citigroup
Oct 30, 25
▲ Buy · 🎯$375
Price at call : $319.55 — upside +17%
Today : $296.42 — upside +27%
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
in progress (365j)
matures : Oct 30, 26
Wells Fargo
Oct 30, 25
■ Equal-Weight neutral · not a buy · 🎯$340
Price at call : $319.55 — gap to target +6%
Today : $296.42 — gap to target +15%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Oct 30, 26
RBC Capital
Aug 1, 25
▲ Outperform · 🎯$409
Price at call : $276.8 — upside +48%
Today : $296.42 — upside +38%
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
in progress (365j)
matures : Aug 1, 26
Wells Fargo
Aug 1, 25
■ Equal-Weight neutral · not a buy · 🎯$265
Price at call : $276.8 — gap to target -4%
Today : $296.42 — gap to target -11%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Aug 1, 26
Wells Fargo
Jun 9, 25
■ Equal-Weight neutral · not a buy · 🎯$245
Price at call : $230.52 — gap to target +6%
Today : $296.42 — gap to target -17%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Jun 9, 26
UBS
May 3, 25
▲ Buy · 🎯$310
Price at call : $240.19 — upside +29%
Today : $296.42 — upside +5%
Expected +29% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 47.1% · +16.6% (102 calls)
+7.4%
stock +7% · XLV +5%
Citigroup
May 3, 25
▲ Buy · 🎯$350
Price at call : $240.19 — upside +46%
Today : $296.42 — upside +18%
Expected +46% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
+7.4%
stock +7% · XLV +5%
RBC Capital
May 2, 25
▲ Outperform · 🎯$392
Price at call : $240.19 — upside +63%
Today : $296.42 — upside +32%
Expected +63% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
+7.4%
stock +7% · XLV +5%
Wells Fargo
Apr 17, 25
■ Equal-Weight neutral · not a buy · 🎯$270
Price at call : $236.88 — gap to target +14%
Today : $296.42 — gap to target -9%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Apr 17, 26
Wells Fargo
Feb 12, 25
■ Equal-Weight neutral · not a buy · 🎯$345
Price at call : $306.36 — gap to target +13%
Today : $296.42 — gap to target +16%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Feb 12, 26
RBC Capital
Jan 14, 25
▲ Outperform · 🎯$481
Price at call : $341.79 — upside +41%
Today : $296.42 — upside +62%
Expected +41% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-5.8%
stock -6% · XLV +12%
RBC Capital
Dec 9, 24
▲ Outperform · 🎯$481
Price at call : $345.6 — upside +39%
Today : $296.42 — upside +62%
Expected +39% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-10.9%
stock -11% · XLV +4%
Citigroup
Oct 31, 24
▲ Buy · 🎯$450
Price at call : $368.42 — upside +22%
Today : $296.42 — upside +52%
Expected +22% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
-15.5%
stock -15% · XLV -2%
RBC Capital
Oct 31, 24
▲ Outperform · 🎯$469
Price at call : $368.42 — upside +27%
Today : $296.42 — upside +58%
Expected +27% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-15.5%
stock -15% · XLV -2%
Citigroup
Oct 1, 24
▲ Buy · 🎯$400
Price at call : $337.69 — upside +18%
Today : $296.42 — upside +35%
Expected +18% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
-11.8%
stock -12% · XLV -6%
Wells Fargo
Aug 27, 24
■ Equal-Weight neutral · not a buy · 🎯$340
Price at call : $328.75 — gap to target +3%
Today : $296.42 — gap to target +15%
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
in progress (365j)
matures : Aug 27, 25
RBC Capital
Aug 16, 24
▲ Outperform · 🎯$401
Price at call : $326.33 — upside +23%
Today : $296.42 — upside +35%
Expected +23% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-12.8%
stock -13% · XLV -12%
RBC Capital
Aug 2, 24
▲ Outperform · 🎯$401
Price at call : $328.68 — upside +22%
Today : $296.42 — upside +35%
Expected +22% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-15.8%
stock -16% · XLV -9%
Citigroup
Aug 2, 24
■ Neutral neutral · not a buy · 🎯$350
Price at call : $328.68 — gap to target +6%
Today : $296.42 — gap to target +18%
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
in progress (365j)
matures : Aug 2, 25
UBS
May 8, 24
▲ Buy · 🎯$385
Price at call : $268.26 — upside +44%
Today : $296.42 — upside +30%
Expected +44% · Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 47.1% · +16.6% (102 calls)
-10.2%
stock -10% · XLV -6%
Citigroup
Apr 3, 24
■ Neutral neutral · not a buy · 🎯$365
Price at call : $322.83 — gap to target +13%
Today : $296.42 — gap to target +23%
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
in progress (365j)
matures : Apr 3, 25
UBS
Feb 16, 24
▲ Buy · 🎯$420
Price at call : $343.76 — upside +22%
Today : $296.42 — upside +42%
Expected +22% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 47.1% · +16.6% (102 calls)
-17.6%
stock -18% · XLV -0%
RBC Capital
Feb 16, 24
▲ Outperform · 🎯$480
Price at call : $343.76 — upside +40%
Today : $296.42 — upside +62%
Expected +40% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-17.6%
stock -18% · XLV -0%
UBS
Dec 7, 23
▲ Buy · 🎯$395
Price at call : $310.18 — upside +27%
Today : $296.42 — upside +33%
Expected +27% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 47.1% · +16.6% (102 calls)
+4.9%
stock +5% · XLV +9%
Wells Fargo
Aug 7, 23
▲ Overweight · 🎯$525
Price at call : $401.52 — upside +31%
Today : $296.42 — upside +77%
Expected +31% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
-18.6%
stock -19% · XLV +10%
RBC Capital
Aug 4, 23
▲ Outperform · 🎯$524
Price at call : $401.52 — upside +31%
Today : $296.42 — upside +77%
Expected +31% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-18.1%
stock -18% · XLV +10%
Credit Suisse
Aug 4, 23
▲ Outperform · 🎯$550
Price at call : $400 — upside +38%
Today : $296.42 — upside +86%
Expected +38% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-17.8%
stock -18% · XLV +11%
Wells Fargo
Jun 16, 23
▲ Overweight · 🎯$550
Price at call : $376.56 — upside +46%
Today : $296.42 — upside +86%
Expected +46% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
-21.4%
stock -21% · XLV +10%
Citigroup
May 8, 23
▲ Buy · 🎯$525
Price at call : $366.86 — upside +43%
Today : $296.42 — upside +77%
Expected +43% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
-26.9%
stock -27% · XLV +7%
RBC Capital
May 8, 23
▲ Outperform · 🎯$531
Price at call : $378.39 — upside +40%
Today : $296.42 — upside +79%
Expected +40% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-26.0%
stock -26% · XLV +7%
Credit Suisse
May 5, 23
▲ Outperform · 🎯$580
Price at call : $378.39 — upside +53%
Today : $296.42 — upside +96%
Expected +53% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-25.5%
stock -25% · XLV +6%
RBC Capital
Feb 17, 23
▲ Outperform · 🎯$579
Price at call : $483.23 — upside +20%
Today : $296.42 — upside +95%
Expected +20% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-28.9%
stock -29% · XLV +10%
Credit Suisse
Feb 17, 23
▲ Outperform · 🎯$680
Price at call : $483.23 — upside +41%
Today : $296.42 — upside +129%
Expected +41% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-28.9%
stock -29% · XLV +10%
RBC Capital
Dec 7, 22
▲ Outperform · 🎯$565
Price at call : $403.88 — upside +40%
Today : $296.42 — upside +91%
Expected +40% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 9% (11 calls matureds) · 📊 on Health : 48.9% · +4.9% (186 calls)
-23.2%
stock -23% · XLV -5%
Credit Suisse
Oct 28, 22
▲ Outperform · 🎯$640
Price at call : $354.3 — upside +81%
Today : $296.42 — upside +116%
Expected +81% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-24.0%
stock -24% · XLV -7%
Credit Suisse
Aug 25, 22
▲ Outperform · 🎯$715
Price at call : $514.63 — upside +39%
Today : $296.42 — upside +141%
Expected +39% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-25.8%
stock -26% · XLV +2%
Citigroup
Jul 8, 22
▲ Buy · 🎯$700
Price at call : $517.12 — upside +35%
Today : $296.42 — upside +136%
Expected +35% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
-24.7%
stock -25% · XLV -1%
Wells Fargo
Jul 30, 21
▲ Overweight · 🎯$930
Price at call : $739.51 — upside +26%
Today : $296.42 — upside +214%
Expected +26% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
-25.1%
stock -25% · XLV -1%
Citigroup
Feb 12, 21
▲ Buy · 🎯$750
Price at call : $649.62 — upside +15%
Today : $296.42 — upside +153%
Expected +15% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
-4.4%
stock -4% · XLV +11%
Jefferies
Feb 5, 21
▲ Buy · 🎯$725
Price at call : $628.68 — upside +15%
Today : $296.42 — upside +145%
Expected +15% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (1 call matured) · 📊 on Health : 48% · +9.7% (98 calls)
-0.6%
stock -1% · XLV +14%
Citigroup
Jul 31, 20
▲ Buy · 🎯$625
Price at call : $524.89 — upside +19%
Today : $296.42 — upside +111%
Expected +19% · Actual +40% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
+40.3%
stock +40% · XLV +25%
Wells Fargo
May 21, 20
▲ Overweight · 🎯$525
Price at call : $466.79 — upside +12%
Today : $296.42 — upside +77%
Expected +12% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
+27.4%
stock +27% · XLV +25%
Citigroup
May 7, 20
▲ Buy · 🎯$525
Price at call : $456.35 — upside +15%
Today : $296.42 — upside +77%
Expected +15% · Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
+32.3%
stock +32% · XLV +25%
Citigroup
Apr 20, 20
▲ Buy · 🎯$480
Price at call : $417.71 — upside +15%
Today : $296.42 — upside +62%
Expected +15% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
+51.8%
stock +52% · XLV +27%
Wells Fargo
Mar 30, 20
▲ Overweight · 🎯$385
Price at call : $350.56 — upside +10%
Today : $296.42 — upside +30%
Expected +10% · Actual +63% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 40% (5 calls matureds) · 📊 on Health : 46% · +2.8% (126 calls)
+62.9%
stock +63% · XLV +32%
Barclays
Mar 26, 20
▲ Overweight · 🎯$430
Price at call : $322.41 — upside +33%
Today : $296.42 — upside +45%
Expected +33% · Actual +77% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 100% (1 call matured) · 📊 on Health : 47.8% · +1.6% (186 calls)
+76.8%
stock +77% · XLV +38%
Citigroup
Mar 20, 20
▲ Buy · 🎯$425
Price at call : $329.01 — upside +29%
Today : $296.42 — upside +43%
Expected +29% · Actual +76% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 50% (10 calls matureds) · 📊 on Health : 56.8% · +16.5% (118 calls)
+76.3%
stock +76% · XLV +46%
JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)